BDX
NYSE · Health Care
Becton Dickinson And Co
$211.88
-1.67 (-0.78%)
Performance
1D
+0.00%
1W
+6.69%
1M
+15.94%
3M
+17.95%
6M
+48.01%
1Y
+51.55%
YTD
+38.25%
Open$209.29
Previous Close$213.55
Day High$214.88
Day Low$208.95
52W High$214.78
52W Low$127.59
Volume—
Avg Volume2.32M
Market Cap57.82B
P/E Ratio61.38
EPS$3.31
SectorHealth Care
Technical Indicators
Full analysis →
SMA 50
$188.21
Above
SMA 200
$167.08
Above
RSI (14)
78.5
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Buy
20 analysts
Price Target
-0.1% upside
Current
$211.88
$211.88
Target
$211.74
$211.74
$118.16
$211.74 avg
$242.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 20.66B | 19.68B | 18.67B |
| Net Income | 1.59B | 1.36B | 2.06B |
| Profit Margin | 7.7% | 7.3% | 11.1% |
| EBITDA | 4.75B | 4.30B | 4.26B |
| Free Cash Flow | — | — | 1.84B |
| Rev Growth | +5.0% | +5.0% | -1.1% |
| Debt/Equity | 0.76 | 0.76 | 0.42 |
Dividend
Dividend Yield1.59%
Annual Dividend$4.16
Payout Ratio71.3%
Frequencysemi-annual
Ex-DividendFeb 13, 2026
Pay DateFeb 23, 2026
About Becton Dickinson And Co
Becton, Dickinson and Company is a leading global medical technology company headquartered in Franklin Lakes, New Jersey, focused on improving medical discovery, diagnostics, and the delivery of care. The company manufactures and sells a broad portfolio of medical devices, instrument systems, and reagents across its three segments: BD Medical, BD Diagnostics, and BD Interventional. Its products include syringes, infusion therapy systems, diagnostic platforms, surgical instruments, and drug delivery solutions used by hospitals, laboratories, and clinicians worldwide. Becton, Dickinson is one of the largest medical technology companies in the world, competing with companies such as Abbott, Baxter, and Medtronic across multiple clinical specialties and geographic markets.
Health Care Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| UNH | UnitedHealth Group Inc | $394.15 | -0.40% | 23.0 | 364.99B |
| ABT | Abbott Laboratories | $109.93 | -3.23% | 40.9 | 192.04B |
| ISRG | Intuitive Surgical Inc | $452.80 | -3.36% | 54.9 | 162.41B |
| SYK | Stryker Corp | $325.87 | -2.75% | 34.0 | 123.21B |
| MDT | Medtronic Plc | $101.80 | -2.90% | 25.6 | 134.11B |
| MCK | Mckesson Corp | $1,060.84 | -1.04% | 26.7 | 122.62B |
BDX Frequently Asked Questions
What does Becton Dickinson do?
Becton Dickinson earns most of its revenue by making the workhorse products of modern medicine — syringes, needles, infusion systems, and diagnostic platforms that appear in almost every hospital and clinic worldwide. Its three segments address different parts of the care continuum: BD Medical focuses on medication management and drug delivery; BD Diagnostics supplies laboratory instruments and test reagents; and BD Interventional offers surgical and vascular devices. Scale and deep integration into hospital supply chains make switching difficult, while the recurring nature of single-use consumables drives predictable revenue streams.
Is BDX stock a good investment?
Becton Dickinson generates stable cash flows from its consumables-heavy business model, which provides resilience through economic cycles. Investors have long valued the company's consistent dividend growth, though the stock carries leverage from past acquisitions, particularly C.R. Bard. The company is working through a strategic portfolio review that may involve divestitures, which could improve free cash flow conversion and reduce debt. Revenue growth has been moderate, and execution on its innovation pipeline will likely determine whether the stock rerates higher.
Who are Becton Dickinson's main competitors?
Abbott Laboratories competes across diagnostics and medical devices in overlapping markets. Baxter International competes in infusion therapy and renal care. Medtronic and Stryker are formidable rivals in the interventional and surgical device segments. Cardinal Health and Owens & Minor compete on the distribution side. In diagnostics specifically, Roche, Siemens Healthineers, and bioMerieux are significant global competitors.
Does Becton Dickinson pay dividends?
Becton Dickinson has paid and increased its dividend for over 50 consecutive years, making it a Dividend King — one of a small group of companies with that distinction. The yield is modest relative to the overall healthcare sector, but the uninterrupted growth streak reflects a business model that consistently generates enough cash to reward shareholders while funding acquisitions and R&D. Management has treated the dividend as a non-negotiable commitment even during periods of elevated debt.
Where is BDX trading today?
BDX last closed at $211.88, down 0.78% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $127.59 and a high of $214.78. The current price represents 97% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
What are analyst ratings for BDX stock?
Among 20 analysts covering BDX, the consensus rating is Buy — 11 rate it a buy, 9 hold, and 0 sell. The average price target sits at $211.74, implying 0% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
How much revenue does Becton Dickinson And Co generate?
Becton Dickinson And Co generated $20.66B in revenue during fiscal year 2026, with $1.59B reaching the bottom line as net income. The net profit margin of 7.7% reflects the competitive nature of its industry.
What is the price-to-earnings ratio for BDX?
BDX trades at a P/E ratio of 61.38 on trailing earnings of $3.31 per share. That's well above the S&P 500 historical average of ~20-25x, which typically signals that investors are pricing in aggressive future growth. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.
How has BDX performed compared to last year?
BDX has been on a strong uptrend over the past year and continues to show momentum. Returns by timeframe: +0.00% (1D), +6.69% (1W), +15.94% (1M), +17.95% (3M), +48.01% (6M), +51.55% (1Y), +38.25% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether BDX is outperforming or lagging the broader market.